ARTICLE | Company News

ChemoCentryx, GlaxoSmithKline deal

January 9, 2012 8:00 AM UTC

GlaxoSmithKline exercised an option for exclusive, worldwide rights to develop and commercialize arthritis compound CCX354 from ChemoCentryx. ChemoCentryx will receive a $25 million option fee, and is eligible for milestones and double-digit royalties. CCX354 is a small molecule CC chemokine receptor 1 (CCR1) antagonist. Details were not disclosed (see BioCentury, Aug. 28, 2006). ...